Thursday, April 11, 2013
This week in therapeutics
Non-small cell lung cancer
Ret proto-oncogene (RET);
oncogenic fusion protein
Preliminary results from an
investigator-initiated Phase II trial suggest small molecule RET inhibitors
could help treat RET fusion-positive lung cancers. Last year, KIF5B-RET
fusions were identified in 1%-2% of patients with NSCLC. In three RET fusion-positive
patients treated with Cometriq
two had a confirmed partial response and the third had stable disease. Next
steps include expanding the clinical trial and continuing patient follow-up.
Inc. markets Cometriq, a small molecule c-Met
receptor tyrosine kinase and VEGF
inhibitor that also inhibits RET, to treat medullary thyroid cancer.
Pharmaceuticals Inc.'s Iclusig
tyrosine kinase inhibitor that also inhibits RET, is in a
separate investigator-led Phase II trial to treat RET fusion-positive NSCLC (see
go, page 1).
Published online April 11, 2013
Patent and licensing status
Drilon, A. et al. Cancer
Discov.; published online March 26, 2013;
Contact: Naiyer A. Rizvi, Memorial Sloan-Kettering Cancer
Center, New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]